4,5-Dihydro-2-thiazolamine → HCID 58614922, compound

HRID 1364682Notes

Reaction equation

HRID 1364682 reaction equation
[Cl:1][C:2]1[CH:3]=[C:4]([CH:8]=[CH:9][C:10]=1[C:11](=[O:26])[NH:12][C:13]1[CH:18]=[CH:17][C:16]([Cl:19])=[C:15]([C:20]2[CH:25]=[CH:24][CH:23]=[CH:22][N:21]=2)[CH:14]=1)[C:5](O)=[O:6].[NH2:27][C:28]1[S:29][CH2:30][CH2:31][N:32]=1>>[Cl:1][C:2]1[CH:3]=[C:4]([C:5]([NH:27][C:28]2[S:29][CH2:30][CH2:31][N:32]=2)=[O:6])[CH:8]=[CH:9][C:10]=1[C:11]([NH:12][C:13]1[CH:18]=[CH:17][C:16]([Cl:19])=[C:15]([C:20]2[CH:25]=[CH:24][CH:23]=[CH:22][N:21]=2)[CH:14]=1)=[O:26]

Participants

3

Reactant 2

HCID 156894,5-Dihydro-2-thiazolamineHCID 668786053-Chloro-4-(4-chloro-3-(pyridin-2-yl)phenylcarbamoyl)benzoic acid

Product 1

HCID 58614922HCID 58614922, compound

Procedure

50 mg of 3-chloro-4-(4-chloro-3-(pyridin-2-yl)phenylcarbamoyl)benzoic acid was coupled to 2-amino-4,5-dihydrothiazole via Procedure G. The product was purified on reverse phase HPLC to yield 2-chloro-N1-(4-chloro-3-(pyridin-2-yl)phenyl)-N4-(4,5-dihydrothiazol-2-yl)terephthalamide. MS (Q1) 471 (M)+.

Workup

  1. customThe product was purified on reverse phase HPLC

Sources & evidence

ORD record
ord-dd1ca45b5c8042398ff3603191f428cc
Source dataset
uspto-grants-2011_02
Patent number
US07888364B2

Reaction notes

Loading…